Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

ViroPharma Falls After FDA Delays Plant Approval

Oct. 22 (Bloomberg) -- ViroPharma Inc. fell 5.1 percent after the U.S. Food and Drug Administration sought additional information following a pre-approval inspection of manufacturing facilities for its Cinryze treatment.

ViroPharma declined 83 cents to $15.36 at 4 p.m. New York time in Nasdaq Stock Market Composite trading. The shares are up 83 percent for the year. The Exton, Pennsylvania-based company said in a statement that it will work “immediately” to respond to the FDA.

Cinryze is administered by infusion every three to four days to prevent swelling attacks in patients with hereditary angioedema, a life-threatening disorder affecting about 6,500 people in the U.S. The drug sells for $4,000 a dose, and if new facilities are allowed to open, sales may top $250 million next year, said Phil Nadeau, an analyst with Cowen & Co. in New York.

“This is a disappointment, as the manufacturing expansion was expected to be approved on its action date yesterday,” Nadeau said in a note to clients today. “The expansion is necessary to increase Cinryze’s capacity from 60,000 doses annually today to 160,000 doses per year.”

ViroPharma said in the statement that it plans to start manufacturing industrial-scale lots “at risk” in the first quarter of next year.

“We remain committed to provide patients with an uninterrupted supply of Cinryze,” said Vincent Milano, chief executive officer at ViroPharma, in the statement.

To contact the reporter on this story: Tom Randall in New York at trandall6@bloomberg.net.

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.